TG and breast cancer: In the breast cancer model, MEP50 loss further diminishes the expression of genes associated with endocrine resistance (NES = −1.28), estrogen signaling (NES = −1.34), and thyroid hormone activity (NES = −1.41) (Fig. 4B).